Trials / No Longer Available
No Longer AvailableNCT00655252
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus |
Timeline
- First posted
- 2008-04-09
- Last updated
- 2011-08-19
Locations
84 sites across 13 countries: United States, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Lebanon, Norway, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00655252. Inclusion in this directory is not an endorsement.